Neurotoxicity of taxanes: Symptoms and quality of life assessment
- 1 January 2004
- journal article
- review article
- Published by Springer Nature in Breast Cancer
- Vol. 11 (1) , 92-99
- https://doi.org/10.1007/bf02968010
Abstract
Paclitaxel (TXL) and docetaxel (TXT), especially TXL, cause neurotoxicity manifested as polyneuropa-thy. In clinical practice, detailed knowledge of the symptoms and effect on quality of life (QOL) of neurotoxicity is crucially important both for diagnosis of neuropathy and for management of patients treated with taxanes. In this review, we summarize the symptoms of neurotoxicity caused by taxanes, and highlight the importance of QOL assessment in breast cancer patients treated with taxanes. The most common feature of taxane neurotoxicity is a predominant sensory distal neuropathy, and the incidence and severity of the neuropathic manifestations appear to be related to dose level and cumulative dose. A mixture of paresthesias and dysesthesias is often prominent, and the complaints include burning dysesthesia, numbness, tingling, and shooting pains, typically in a stocking-glove distribution. In contrast to sensory disturbances, motor neuropathy is not well recognized, and is believed to be much less common than sensory neuropathy. Weakness is usually mild, and distal motor neuropathy caused by taxanes rarely affects patients’ activities of daily living. The effect of neurotoxicity on QOL is not fully understood, as no study has specifically assessed QOL in terms of neurotoxicity. There is therefore a clear need to collect more detailed data about QOL using well validated, reliable instruments. This will enable us to provide the information that patients require when treatment decisions are being made, and will help in the pursuit of the ameliorative interventions.Keywords
This publication has 45 references indexed in Scilit:
- Multicenter Phase II Trial of Weekly Paclitaxel in Women With Metastatic Breast CancerJournal of Clinical Oncology, 2001
- Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancerAnnals of Oncology, 2001
- Phantom Limb Pain as a Manifestation of Paclitaxel NeurotoxicityMayo Clinic Proceedings, 2000
- Managing the Neurotoxicity of Paclitaxel (Taxol®) and Docetaxel (Taxotere®) with Neurotrophic FactorsCancer Investigation, 2000
- A phase I–II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancerAnnals of Oncology, 1998
- Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.Journal of Clinical Oncology, 1998
- The TaxoidsDrugs, 1998
- Paclitaxel neurotoxicity: clinical and neurophysiological study of 23 patients.The Italian Journal of Neurological Sciences, 1997
- Motor neuropathy due to docetaxel and paclitaxelNeurology, 1996
- Paclitaxel (Taxol) induces cumulative mild neurotoxicityEuropean Journal Of Cancer, 1994